Deutsche Märkte öffnen in 8 Stunden 29 Minuten

Mesoblast Limited (MESO)

NasdaqGS - NasdaqGS Echtzeitpreis. Währung in USD
Zur Watchlist hinzufügen
8,52+0,35 (+4,28%)
Börsenschluss: 04:00PM EDT
8,52 0,00 (0,00%)
Nachbörse: 06:21PM EDT

Mesoblast Limited

55 Collins Street
Level 38
Melbourne, VIC 3000
Australia
61 3 9639 6036
https://www.mesoblast.com

Sektor(en)Healthcare
BrancheBiotechnology
Vollzeitmitarbeiter83

Leitende Angestellte

NameTitelZahlenAusgeübtGeburtsjahr
Dr. Silviu Itescu FACP, FACRA, FRACP, MBBS (Hons)Founder, CEO, MD, Chairman of Scientific Advisory Board & Executive Director751,93kN/A1957
Dr. Eric A. Rose M.D.Chief Medical Officer & Executive Director636,63kN/A1951
Mr. Andrew Chaponnel B.Com.Interim Chief Finance OfficerN/AN/AN/A
Mr. Peter T. Howard B.Sc., L.L.B., LLB (Hons)General Counsel & Corporate ExecutiveN/AN/A1968
Mr. Roger D. Brown BAHead of Spinal Orthopedic DisordersN/AN/AN/A
Mr. Michael Schuster BSc, M.B.A., MSHead of Pharma PartneringN/AN/A1977
Ms. Geraldine Storton B.Sc., M.B.A., MMSHead of Regulatory Affairs & Quality ManagementN/AN/AN/A
Mr. Justin Horst B.S.Head of ManufacturingN/AN/AN/A
Ms. Niva Sivakumar B.Com., L.L.B.Joint Company SecretaryN/AN/AN/A
Mr. Paul Hughes BPHARMJoint Company SecretaryN/AN/AN/A
Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.

Corporate Governance

Mesoblast Limiteds ISS Governance QualityScore, Stand 1. Mai 2024, lautet 6. Die grundlegenden Scores sind Audit: 9, Vorstand: 4, Shareholderrechte: 10, Kompensation: 8.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.